Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

Stock Information for Q32 Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Q32 Bio Inc.

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
Q32 Bio Announces $55 Million Private Placement Financing
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.